Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.

NKTR shares climb to $9.54 amid investor optimism and Phase IIb REZOLVE-AD results; EPS forecasts up 10.5% in 30 days.

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...